Trial · NCT07450469
Field Study on Intravenous Iloprost for Treatment of Severe Frostbite at High Altitude
NCT07450469, Not yet recruiting, Institute of Mountain Emergency Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Field Study on Intravenous Iloprost for Treatment of Severe Frostbite at High Altitude. Trials, record NCT07450469. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07450469
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Field Study on Intravenous Iloprost for Treatment of Severe Frostbite at High Altitude
- NCT number
- NCT07450469
- Status
- Not yet recruiting
- Enrollment
- 10 participants, estimated
- Lead sponsor
- Institute of Mountain Emergency Medicine
- Conditions
- Frostbite, Altitude, Field Physician Care
- Interventions
- Iloprost (Ilomedin, BAYQ6256)
- First posted
- 2026-03-04
- Last updated
- 2026-03-09
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of frostbite presentations with severe frostbite (Grade 3-4) at Everest ER | from enrolment to the end of treatment at 1 week | Patients will be assessed using Cauchy classification. Proportion of patients presenting with grade 3 + 4 frostbite in relation to the total number of patients with frostbite presenting at Everest ER Unit/format: proportion (%) |
| Primary | Proportion of eligible severe frostbite patients who complete ≥1 field iloprost treatment round | From enrolment to 1 week after beginning of treatment | The proportion of the number of patients who successfully completed at least one round of iloprost treatment under field conditions in relation to the number of eligible patients. Denominator explicitly: eligible grade 3-4 patients (Cauchy classification) Unit/format: proportion (%) |
| Primary | Time from thawing to initiation of iloprost treatment under field conditions | From enrolment to the end of treatment at day 1 | Unit/format: time (hours or minutes) |
| Primary | Proportion of iloprost-treated patients with mild adverse effects during/after ≥1 treatment round in the field setting | From enrollment to the end of treatment at 1 week | Unit/format: proportion (%) Adverse effects will be graded using CTCAE (CTCAE = Common Terminology Criteria for Adverse Events) severity criteria. Proportion of mild adverse effects in the field setting will then be compared with in-hospital settings. |
| Primary | Proportion of iloprost-treated patients with severe adverse effects during/after ≥1 treatment round in the field | From enrolment to the end of treatment at 1 week | Unit/format: proportion (%) Adverse effects will be graded using CTCAE (Common Terminology Criteria for Adverse Events) severity criteria. In a second step proportion of severe adverse events during field treatment will be compared with proportions of in-hospital treatment |
| Primary | Proportion of patients discontinuing field iloprost treatment (overall) and documented reasons for discontinuation | From enrolment to end of treatment at 1 week | Proportion of discontinued field treatments in relation to all initiated field treatments. Unit/format: proportion (%) + categorical reason counts |
| Primary | Proportion of iloprost treatment discontinuations attributable to adverse effects in the field | From enrolment to end of treatment at 1 week | Unit/format: proportion (%) Number of treatments discontinued due to adverse reactions in relation to all treatments discontinued (both in the field) |
| Primary | Qualitative description of logistical constraints and solutions from field notes and staff reports | From enrolment to end of treatment at 1 week | Notes and reports will be analysed using a thematic analysis approach to categorise logistical challenges. Reported as: themes/categories with illustrative summaries (qualitative) |
| Primary | Frequency of logistical challenges during field iloprost implementation | from enrolment to end of treatment at 1 week | Number of logistical challenges, classified using a logistical challenge themes arising from qualitative analysis of field notes and staff reports. Possible themes expected include challenges related to equipment availability or functionality, personnel issues, environmental barriers. Reported as: counts (n) and percentages (%) (number of challenges within one respective category in relation to all registered logistical challenges) |
| Primary | Proportion of logistical challenges resolved during the study period | from enrolment to end of treatment at week 1 | Number of logistical challenges resolved in relation to all challenges recorded within one defined logistical challenge theme. Reported as: percentage (%) The logistical challenges themes will be arising from qualitative analysis of field notes and staff reports. |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07450469
GET https://conductscience.org/api/trials/v1/NCT07450469/registered